Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02100956 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02100956 is a Phase 2 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 8 participants.
The verdict
NCT02100956, a Phase 2 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the effect of oxytocin given into the spinal fluid on pain and areas and intensity of hyperalgesia and allodynia in patients with chronic neuropathic pain.
Interventions
- DRUG oxytocin 100 micrograms
- DRUG Normal Saline (preservative free)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-06-19 |
| Est. Completion | 2022-10-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02100956
The ClinicalTrials.gov registry entry for NCT02100956 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which oxytocin 100 micrograms is the first listed.
NCT02100956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02100956 about?
NCT02100956 is a clinical study titled "Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain". The purpose of the study is to determine the effect of oxytocin given into the spinal fluid on pain and areas and intensity of hyperalgesia and allodynia in patients with chronic neuropathic pain.
What is the current status of trial NCT02100956?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2014-06-19. Estimated completion is 2022-10-10.
What interventions are being tested in trial NCT02100956?
The interventions under investigation include: oxytocin 100 micrograms (DRUG), Normal Saline (preservative free) (DRUG).
Who is sponsoring clinical trial NCT02100956?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.